Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Ki-67 Antigen. Found 8 abstracts

Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer prevention research (Philadelphia, Pa). 2017 Jun;10(6):345-54.   PMCID: PMC5758862
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 2009 Jul;27(19):3177-84.   PMCID: PMC2716939
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. Journal of Clinical Oncology. 2004 Jun;22(11):2133-40.
Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002 May;8(5):1148-54.
Le Voyer T, Rouse J, Lu Z, Lifsted T, Williams M, Hunter KW. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics. 2001 Jun 15;74(3):253-61.
Liu SC, Sauter ER, Clapper ML, Feldman RS, Levin L, Chen SY, Yen TJ, Ross E, Engstrom PF, Klein-Szanto AJ. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):597-603.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Ki-67 Antigen

Ki-67 Antigen Male pathology analysis Non-US Gov't Support metabolism therapeutic use US Gov't Support-PHS Prostatic Neoplasms Immunohistochemistry US Gov't Support-Non-PHS Biological Tumor Markers Combined Modality Therapy Hormonal Antineoplastic Agents Tumor Biomarkers genetics Aged Female Human Middle Aged Cell Division chemistry Gene Expression Treatment Outcome Neoplasm Staging Survival Analysis Adult Predictive Value of Tests Prognosis Epithelial Cells Prostate-Specific Antigen drug therapy radiotherapy Proto-Oncogene Proteins c-mdm2 Tumor Suppressor Protein p53 Androgen Antagonists Time Factors Drug Administration Schedule Paclitaxel therapy Polyethylene Glycols Prospective Studies drug effects Phosphoproteins Nuclear Antigens cytology Analysis of Variance Phosphorylation Blood Vessels Colonoscopy Oral Administration Animal Radiotherapy blood supply adverse effects me [Metabolism] CD31 Antigens In Situ Nick-End Labeling Cohort Studies Colorectal Neoplasms ROC Curve Kaplan-Meier Estimate Apoptosis Gastrointestinal Hormones Peptides Antineoplastic Combined Chemotherapy Protocols Cyclin-Dependent Kinase Inhibitor p27 diagnostic imaging bcl-2-Associated X Protein Genetic Crosses di [Diagnosis] Guanylyl Cyclase C Agonists Chromosome Mapping Genotype Nuclear Proteins Inbred Strains Mice Cyclooxygenase 2 Cell Adhesion Molecules Cyclin-Dependent Kinase Inhibitor p16 Non-Histone Chromosomal Proteins mo [Mortality] Genetic Predisposition to Disease Cyclic GMP pharmacology Treatment Failure blood Cyclin D1 Doxorubicin Neoplasm Invasiveness Multivariate Analysis Follow-up studies Histone Deacetylases 80 and over Aged Enterotoxin Receptors Area Under Curve Microfilament Proteins Quantitative Trait Breast Neoplasms Hydroxamic Acids Carcinoma in Situ Dose Fractionation mortality administration & dosage Mice Natriuretic Peptides tu [Therapeutic Use] Oral Leukoplakia Experimental Mammary Neoplasms Cyclophosphamide Proportional Hazards Models Colon Rectum prevention & control Mouth Mucosa Healthy Volunteers Proto-Oncogene Proteins c-bcl-2 rt [Radiotherapy] Cyclin-Dependent Kinase Inhibitor p21 Computer-Assisted Image Interpretation Follow-Up Studies
Last updated on Sunday, August 09, 2020